Urotensin II and cardiovascular diseases

被引:37
|
作者
Thanassoulis, G [1 ]
Huyhn, T [1 ]
Giaid, A [1 ]
机构
[1] McGill Univ, Montreal Gen Hosp, Dept Med, Montreal, PQ H3G 1A4, Canada
关键词
vascular physiology; atherosclerosis; coronary artery disease; heart failure; metabolic syndrome;
D O I
10.1016/j.peptides.2004.05.027
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Urotensin II (UII) has been found to be a potent vasoactive peptide in humans and in a number of relevant animal models of cardiovascular disease such as the mouse, rat and other non-human primates. This peptide with structural homology to somatostatin was first isolated from the urophysis of fish and was recently found to bind to an orphan receptor in mouse and human. Initially found to have potent vasoconstrictive activities in a variety of vessels from diverse species, it has also been shown to exert vasodilatation in certain vessels in the rat and human by various endothelium-dependent mechanisms. The various vasoactive properties of UII suggest that the peptide may have a physiological role in maintaining vascular tone and therefore may have a role in the pathophysiology of a number of human diseases such as heart failure. Moreover, UII has also been implicated as a mitogen of vascular smooth muscle cells suggesting a deleterious role in atherosclerosis and coronary artery disease. In addition, there is evidence to demonstrate that UII has multiple metabolic effects on cholesterol metabolism, glycemic control and hypertension and therefore may be implicated in the development of insulin resistance and the metabolic syndrome. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:1789 / 1794
页数:6
相关论文
共 50 条
  • [1] Urotensin-II and cardiovascular diseases
    Nicolas Bousette
    Adel Giaid
    Current Hypertension Reports, 2006, 8
  • [2] Urotensin-II and cardiovascular diseases
    Bousette, Nicolas
    Giaid, Adel
    CURRENT HYPERTENSION REPORTS, 2006, 8 (06) : 479 - 483
  • [3] Role of urotensin II in atherosclerotic cardiovascular diseases
    Pakala, Rajbabu
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2008, 9 (03) : 166 - 178
  • [4] The role of urotensin II in cardiovascular and renal physiology and diseases
    Zhu, Yi-Chun
    Zhu, Yi-Zhun
    Moore, Philip Keith
    BRITISH JOURNAL OF PHARMACOLOGY, 2006, 148 (07) : 884 - 901
  • [5] Human Urotensin II Promotes Hypertension and Atherosclerotic Cardiovascular Diseases
    Watanabe, Takuya
    Arita, Shigeko
    Shiraishi, Yuji
    Suguro, Toshiaki
    Sakai, Tetsuo
    Hongo, Shigeki
    Miyazaki, Akira
    CURRENT MEDICINAL CHEMISTRY, 2009, 16 (05) : 550 - 563
  • [6] Urotensin II in cardiovascular regulation
    Russell, Fraser D.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2008, 4 (04) : 775 - 785
  • [7] Urotensin II in the cardiovascular system
    Richards, AM
    Charles, C
    PEPTIDES, 2004, 25 (10) : 1795 - 1802
  • [8] Urotensin II: a cardiovascular and renal update
    Carmine, Zoccali
    Mallamaci, Francesca
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2008, 17 (02): : 199 - 204
  • [9] Urotensin-II and cardiovascular remodeling
    Papadopoulos, Panayiota
    Bousette, Nicolas
    Giaid, Adel
    PEPTIDES, 2008, 29 (05) : 764 - 769
  • [10] Cardiovascular effects of urotensin II in different brain areas
    Lu, Y
    Zou, CJ
    Huang, DW
    Tang, CS
    PEPTIDES, 2002, 23 (09) : 1631 - 1635